dickmidle- MBIO
I wonder what the treatment would bring in revenues, as it's only one time. Seems if we go by 131M worldwide births/year, that around 1700 max new patient opportunity/year. Of course this is all assuming Mustang has sole worldwide licensing rights from St Jude. Also the company is losing around $1.43/year, plus whatever licensing costs are from St Jude, so it seems around $50M+/year profit just to break even. Then the question is, how many of these 1700 or so patients/year would MBIO get- maybe 1/3 in third world countries where they wouldn't even know the newborn has the disease.
It seems to me, that even if treatment costs $50,000/patient, and assuming MBIO treats 1100-1200 patients/year ongoing, that there wouldn't be huge profits yet. I feel MBIO would have to find more uses for the drug to get to $20+, and in the meantime, who knows how much more than $5-$10 the stock is worth. With FDA approval 2.5+ years away, this is definitely a speculative buy here.
News 
Market Data 
Discover 
